Ortin Laboratories Limited

ORTINLAB

INE749B01020

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:51 31/05/2024 pm IST			5-day change	1st Jan Change
17 ^INR	-2.47%		-7.36%	-26.15%

17/02	Ortin Laboratories Limited Announces Board Appointments	CI
13/02	Ortin Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Ortin Laboratories Limited Appoints Pottur Sujatha as Additional Director

December 05, 2020 at 06:06 pm IST

Ortin Laboratories Limited announced that at meeting the company has approved appointment of Ms. Pottur Sujatha as Additional Director of the Company in independent capacity with effective 05.12.2020 (Disclosure as required w/r 30 of SEBI (LODR) Regulations is annexed).

Latest news about Ortin Laboratories Limited

Ortin Laboratories Limited Announces Board Appointments	17/02	CI
Ortin Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02	CI
Ortin Laboratories Limited Appoints Divya Purswani as Company Secretary and Compliance Officer	09/02	CI
Ortin Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	14/11	CI
Ortin Laboratories Limited Announces Executive Changes	10/11	CI
Ortin Laboratories Limited Appointment of Harish Sharma as Company Secretary	10/23/10	CI
Ortin Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/23/14	CI
Drugs Control Authority Cancels Ortin Laboratories' Manufacturing License	11/23/11	MT
Drugs Control Administration, Government of Telangana Cancels Manufacturing License of Ortin Laboratories Limited	11/23/11	CI
Ortin Laboratories Limited Announces Resignation of Nitesh Kumar Sharma as Company Secretary/Compliance Officer	13/23/13	CI
Ortin Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	30/23/30	CI
Ortin Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14	CI
Ortin Laboratories Limited Announces Resignation of J R K Panduranga Rao as Independent Director	29/22/29	CI
Ortin Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/22/14	CI
Ortin Laboratories Limited Announces Cessation of Bh. Satyanarayana Raju and G. Venkata Ramana, Directors	19/22/19	CI
Ortin Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	13/22/13	CI
Ortin Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022	30/22/30	CI
Ortin Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/22/14	CI
Ortin Laboratories Limited Announces Demise of Mohan Krishna Murthy, Whole-Time Director	29/21/29	CI
Ortin Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	13/21/13	CI
Ortin Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	09/21/09	CI
Ortin Laboratories Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	13/21/13	CI
Ortin Laboratories Limited Appoints Mr. S. Srinivas Kumar as CFO	01/21/01	CI
Ortin Laboratories Limited Announces Management Changes	01/21/01	CI
Ortin Laboratories Limited Appoints Pottur Sujatha as Additional Director	05/20/05	CI

Chart Ortin Laboratories Limited

Duration

Period

More charts

Company Profile

Ortin Laboratories Limited is engaged in manufacturing and trading of pharmaceuticals, drugs, and intermediates. It manufactures a range of pharmaceutical formulations of tablets, capsules, syrups, and dry powders. The Company's products include Acefinac, ACEFINAC-CZ, ACEFINAC-P, ACEFINAC-SP, ACTAZID, ACTY-P, ALERFEX-120, ALERFEX-180, ALERGID, ALERGID- L, AMLOBID, CARBAMOL, CARISNIL, CALDY-C AZITIN-500, DOCEF-200, GLYCITROL, GLYCITROL-M, LORACT, MEBOL, NEUROCOB, FERUP, IRFER Z, MINVITA-B, NILCID, ORICILLIN-DX, PEG POWDER, PEG-D POWDER, ALKASIT, COF-XL, DECODIL, ENCENIL and OROMOX DRY SYRUP. Its formulations include Anti Diabetics, Anti Allergics, Anti Anginal and Cardiovascular, Analgesics and Antipyretics, and Anti Biotics-Quinolones. Its active pharmaceutical ingredient (API) intermediates include Anti retro viral, Grignard, Diborane, Ciprofloxacin and Tramadol. It is also manufacturing for different importers to market their products in Russia, Ukraine, Kajakistan and South America.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ORTIN LABORATORIES LIMITED	-26.15%	1.66M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B